Olivier Martinon is the Vice President of External Innovation & Strategic Research Alliances for Zoetis. He has a passion for innovation coupled with deep roots in veterinary sciences across the development of recombinant and vectored vaccines as well as monoclonal antibodies. 

Since joining Zoetis, formally, Pfizer Animal Health, in 2006, Olivier has held a variety of roles. He most recently led the development of Librela & Lenivia, approved as the first monoclonal antibodies to alleviate osteoarthritis in dogs. He managed the entire biotherapeutic portfolio including mAbs, proteins and peptides in his role as First Biopharma Council Chairman. He previously also played the project leader role in the development of Cytopoint, the monoclonal treatment for allergic itch in dogs.

Prior to joining Zoetis, Olivier worked on the development of recombinant and live vector vaccines at Merial in both France and the United States.  He became the New Antigen department leader for MERIAL. Previously, he trained in Molecular Biology with CIRAD working on eradication programs of cattle paramyxoviruses in Africa before joining Virbac as an Immunology/Molecular Biology Scientist (under CIFFRE contract).

Olivier currently lives close to Grand Rapids Michigan with his wife Nathalie (their 3 sons being all grown up) and enjoys birdwatching, trekking, and gardening in his free time.